Thymosin Alpha-1 is an immune-signaling peptide, not a muscle drug - here is the unredacted safety file.

Start here

Most of what gets posted online about Thymosin Alpha-1 mixes it up with three or four other peptides and sells you something. Here is the plain version. Thymosin Alpha-1 (often shortened to Tα1) is a small immune-signaling peptide your body already makes. It does not build muscle and it is not a growth peptide - it is an immune modulator, meaning it nudges your immune system rather than your physique. It has been studied for about forty years and is sold abroad as a generic drug called thymalfasin, mostly for chronic hepatitis and as an immune helper alongside other treatments. It is not approved by the FDA in the United States. The research is real but uneven, and the biggest, most careful study (a 2025 sepsis trial) found no benefit. People mainly report mild injection-site redness; what people report - including the downsides - lives on the effects page. This site is a digest of the studies, with every number cited.

What the Thymosin Alpha-1 record actually shows

Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated peptide cleaved in your body from a larger precursor protein called prothymosin alpha (the parent molecule it is snipped out of) ^[1]. Goldstein and colleagues first isolated it from calf thymus and worked out its full sequence in 1977 ^[1]. The thymus is the small gland behind the breastbone where T-cells (the immune system's coordinating and killing cells) are trained, which is the clue to what this peptide does.

Mechanistically it works at the seam between innate and adaptive immunity. It signals through Toll-like receptors (sensors on immune cells that detect danger), notably TLR2 and TLR9, on dendritic cells (the immune system's scouts that show threats to T-cells) ^[5]. That pushes those scouts to mature and present antigen, which in turn matures T-cells. In parallel it switches on an enzyme called IDO (indoleamine 2,3-dioxygenase) that generates a calming, regulatory arm ^[5]. The net effect is dual: it can restore immunity that has gone quiet while damping immunity that has gone into overdrive. That is the whole reason it has been tried in such different settings - hepatitis, sepsis, COVID-19, cancer support.

The honest headline for this domain is the safety-and-tolerability one: across more than 600,000 patients in post-marketing data, Thymosin Alpha-1 is described as well tolerated, with mild injection-site reactions as the dominant adverse event ^[9]. That is the good news. The caveat, stamped in plain sight, is the thymosin alpha 1 side effects reality check below.

The finding that tempers everything: a null sepsis trial

If you read one number on this site, read this one. The phase-3 TESTS trial enrolled 1,106 adults with sepsis across 22 centres and found no statistically significant difference in 28-day mortality between Thymosin Alpha-1 (23.4%) and placebo (24.1%): hazard ratio 0.99 (95% CI 0.77-1.27), P=0.93 ^[3]. This was the largest and most rigorous sepsis trial of the peptide to date, and it came back null.

That matters because an earlier, smaller trial looked encouraging. The ETASS trial (361 patients) reported 28-day mortality of 26.0% with Thymosin Alpha-1 versus 35.0% in controls - about a 9-point gap, but one that did not clear conventional significance (P=0.062) ^[2]. When a promising small signal evaporates in a large rigorous trial, the large trial wins. We are not going to bury that under marketing copy. The strongest, most consistent evidence is in chronic viral hepatitis, not sepsis - and even there the picture is mixed.

Not the same molecule: the conflation guard

Thymosin Alpha-1 gets confused with almost every peptide that has 'thymo' in the name. They are different molecules. Thymosin Alpha-1 is a 28-amino-acid immune modulator. Thymosin beta-4 (sold as TB-500) is a different 43-amino-acid peptide that binds actin and is involved in tissue repair - and it, not Thymosin Alpha-1, is the one on the WADA prohibited list. Thymulin (also called FTS) is a zinc-dependent nonapeptide. Thymopentin (TP-5) is a pentapeptide. Thymalin is a separate bovine thymic-extract preparation entirely. Prothymosin alpha is the larger precursor protein Thymosin Alpha-1 is cleaved from. Same neighborhood, different addresses. The full side-by-side is on the faq, and the deep version is in the Thymosin Alpha-1 research.

What this file is, and is not

This is an editorial digest. We summarize the published research on Thymosin Alpha-1 and stamp the caveats where they belong. We do not sell anything, we do not run a clinic, and we do not give a human dose - doses appear only as third-person research data ('studied at X mg in [population] by [route]'). If a claim is not in a cited study, it is not on this page. For the reported real-world layer, clearly labeled anecdotal, see the Thymosin Alpha-1 effects page; for the full source list, the Thymosin Alpha-1 references.